2025 年第 2 期 第 20 卷

血清载脂蛋白C1和白细胞介素6及鳞状细胞癌抗原在宫颈癌诊断中的价值研究

Study on the value of serum apolipoprotein C1, interleukin-6 and squamous cell carcinoma antigen in the diagnosis of cervical cancer

作者：张培莉1鞠瑛2陈兰兰2刘义庆2彭美玉1

英文作者：Zhang Peili1 Ju Ying2 Chen Lanlan2 Liu Yiqing2 Peng Meiyu1

单位：1山东第二医科大学基础医学院山东省高等学校免疫微环境与炎症性疾病研究特色实验室，潍坊261053；2山东第一医科大学附属省立医院临床医学检验部，济南250021

英文单位：1School of Basic Medical Sciences Shandong Second Medical University Characteristic Laboratory of Immune Microenvironment and Inflammatory Disease Research of Higher Education Institution of Shandong Province Weifang 261053 China; 2Department of Clinical Medical Laboratory Provincial Hospital Affiliated to Shandong First Medical University Jinan 250021 China

关键词：宫颈癌；血清载脂蛋白C1；白细胞介素6；鳞状细胞癌抗原

英文关键词：Cervicalcancer;SerumapolipoproteinC1;Interleukin-6;Squamouscellcarcinomaantigen

• 摘要：

• 目的 分析血清载脂蛋白C1（APOC1）和白细胞介素6（IL-6）及鳞状细胞癌抗原（SCC）在宫颈癌诊断中的价值。方法 选取2023年4月至2024年6月在山东第一医科大学附属省立医院就诊的宫颈癌患者74例作为宫颈癌组，同时选取60名体检健康者作为对照组。比较2组APOC1、IL-6和SCC水平，分析宫颈癌患者血清APOC1、IL-6和SCC水平与临床病理参数的关系，采用受试者工作特征曲线评估APOC1、IL-6、SCC单独及联合检测对宫颈癌的诊断价值，并对血清不同表达水平患者发生宫颈癌的危险程度进行比较。结果 宫颈癌组血清APOC1、IL-6和SCC水平均高于对照组［89.00（64.67,169.17）mg/L比46.84（27.78，64.15）mg/L、65.49（39.88,125.20）ng/L比34.04（22.28,55.35）ng/L、1.81（1.03,4.03）μg/L比1.01（0.76，1.50）μg/L］ ，差异均有统计学意义（Z=6.130、5.096、4.779，均P<0.001）。国际妇产科联盟分期Ⅲ期患者血清APOC1与IL-6水平明显高于Ⅰ～Ⅱ期患者，低分化患者血清APOC1水平明显高于中高分化患者，鳞状细胞癌患者SCC水平高于腺癌组，差异均有统计学意义（均P<0.05）。血清APOC1、IL-6和SCC联合检测诊断宫颈癌的曲线下面积大于任何一项单独检测（0.900比0.809、0.757、0.741），三者联合检测的敏感度和特异度也分别大于单项检测，差异均有统计学意义（均P<0.05）。血清APOC1、IL-6和SCC高水平患者发生宫颈癌的危险程度是低水平患者的9.76、5.94、3.92倍。结论 宫颈癌患者血清中APOC1、IL-6、SCC水平明显升高，血清水平对肿瘤分期、肿瘤类别和分化程度具有一定的预测价值；APOC1、IL-6、SCC的联合检测可以提高宫颈癌的诊断效能。

• Objective To investigate the diagnostic value of serum apolipoprotein C1 (APOC1), interleukin-6 (IL-6) and squamous cell carcinoma antigen (SCC) in cervical cancer. Methods A total of 74 patients with cervical cancer who were treated in the Provincial Hospital Affiliated to Shandong First Medical University from April 2023 to June 2024 were selected as the cervical cancer group, and 60 healthy people were selected as the control group. The levels of APOC1, IL-6 and SCC in the two groups were compared, and the relationship between serum APOC1, IL-6 and SCC levels and clinicopathological parameters in patients with cervical cancer was analyzed. The receiver operating characteristic curve was used to evaluate the diagnostic value of single and combined detection of APOC1, IL-6 and SCC for cervical cancer, and the risk degree of cervical cancer in patients with different serum expression levels was compared. Results The levels of APOC1, IL-6 and SCC in cervical cancer group were higher than those in control group ［89.00(64.67, 169.17)mg/L vs 46.84(27.78, 64.15)mg/L, 65.49(39.88, 125.20)ng/L vs 34.04(22.28, 55.35)ng/L, 1.81(1.03, 4.03)μg/L vs 1.01(0.76, 1.50)μg/L］(Z=6.130, 5.096, 4.779, all P<0.001). The serum APOC1 and IL-6 levels in International Federation of Gynecology and Obstetrics (FIGO) stage Ⅲ patients were significantly higher than those in FIGO stage Ⅰ-Ⅱ patients. The serum APOC1 level in poorly differentiated patients was significantly higher than that in moderately well differentiated patients. The SCC level in squamous cell carcinoma patients was higher than that in adenocarcinoma patients (all P<0.05). The area under the curve of combined detection of APOC1, IL-6 and SCC in the diagnosis of cervical cancer was larger than that of any one of them alone (0.900 vs 0.809, 0.757, 0.741), and the sensitivity and specificity of combined detection of the three markers were also higher than those of single detection (all P<0.05). The risk of cervical cancer in patients with high levels of APOC1, IL-6 and SCC was 9.76, 5.94 and 3.92 times higher than those with low levels of APOC1, IL-6 and SCC. Conclusions The serum levels of APOC1, IL-6 and SCC are significantly increased in patients with cervical cancer. The serum levels have certain predictive value for tumor stage, tumor type and differentiation degree. The combined detection of APOC1, IL-6 and SCC can improve the diagnostic efficiency of cervical cancer.